Volume 77, Issue 1 pp. 327-330
NEWS & VIEWS
Free to Read

Medical algorithm: Aspergillus fumigatus components in the diagnosis of allergic bronchopulmonary aspergillosis

Raphael Lukaszewicz

Raphael Lukaszewicz

Department of Pulmonary, Thoracic Oncology and Respiratory Intensive Care, CHU Rouen, Rouen, France

Search for more papers by this author
Guillaume Mahay

Guillaume Mahay

Department of Pulmonary, Thoracic Oncology and Respiratory Intensive Care, CHU Rouen, Rouen, France

Search for more papers by this author
Olivier Boyer

Olivier Boyer

Department of Immunology and Biotherapy, Normandie Univ, UNIROUEN, Inserm U1234, CHU Rouen, Rouen, France

Search for more papers by this author
Jérémie Martinet

Corresponding Author

Jérémie Martinet

Department of Immunology and Biotherapy, Normandie Univ, UNIROUEN, Inserm U1234, CHU Rouen, Rouen, France

Correspondence

Jérémie Martinet, Department of Immunology and Biotherapy, Normandie Univ, UNIROUEN, Inserm U1234, CHU Rouen, F-76000 Rouen, France.

Email: [email protected]

Search for more papers by this author
First published: 12 July 2021
Citations: 5
First page image

CONFLICT OF INTEREST

Dr. Lukaszewicz reports non-financial support from Astra Zeneca, non-financial support from Chiesi, non-financial support from ALK, personal fees and non-financial support from GSK, non-financial support from Novartis, outside the submitted work; Dr. Mahay reports grants, personal fees and non-financial support from Astra Zeneca, personal fees and non-financial support from Sanofi, personal fees and non-financial support from Chiesi, personal fees and non-financial support from ALK, personal fees and non-financial support from Menarini, personal fees and non-financial support from GSK, grants from Gossamer Bio, personal fees and non-financial support from Novartis, outside the submitted work; Dr. Boyer reports grants and personal fees from CSL Behring, personal fees from BMS, personal fees from Elsevier, grants from Ra Pharma, grants from Grifols, grants and personal fees from Argenx, outside the submitted work; Dr. Martinet reports non-financial support from Thermo Fisher, non-financial support from Stallergenes, non-financial support from Astrazeneca, non-financial support from Novartis, outside the submitted work.

The full text of this article hosted at iucr.org is unavailable due to technical difficulties.